“Prostate Cancer Biomarker Enrichment and Treatment Selection”
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
Drug - Adavosertib
300mg days 1-5, 8-12 q21 days
Drug - Savolitinib
300mg once daily, orally.
Drug - Darolutamide
600mg twice daily, orally.
Drug - CFI-400945
Dose level assigned at enrollment on 1 wk on and 1 wk off. Cycle 1 will consist of a 14-day run-in with CFI-400945 at 48 mg/day for 7 days and followed by a 7-day period without CFI-400945 administration.
Drug - Ipatasertib
400mg daily 3 weeks on, 1 week off
Drug - Durvalumab and Tremelimumab
Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study